A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Non-Hodgkin's Lymphoma (NHL)

PHASE1TerminatedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

March 31, 2008

Study Completion Date

October 31, 2009

Conditions
Lymphoma
Interventions
DRUG

CAT-8015

The dose level of the initial cohort will be 5 μg/kg so cohorts will be dosed at 5, 10, 20, 30, 40, 50, 60…μg/kg until toxicity supervenes.

Trial Locations (3)

20892

NCI, National Institutes of Health, Bethesda

90211-1850

Tower Hematology Oncology Medical Group, Beverly Hills

93-510

Kalinika Hemotologii Uniwersytetu Medycznego, Lodz

Sponsors

Lead Sponsor

All Listed Sponsors
lead

MedImmune LLC

INDUSTRY